Effect of @entity1955 treatment on in vitro fertilization and pregnancy outcome in XXXX @entity1 with @entity1375 undergoing in vitro fertilization/intracytoplasmic sperm injection.

@entity1 @entity1375 @entity249 @entity1955 @entity2016
OBJECTIVE: To investigate whether @entity1955 ( @entity2016 ) treatment has beneficial effects on IVF results and pregnancy outcome in @entity249 @entity1 with @entity1375 undergoing IVF/intracytoplasmic sperm injection (ICSI). DESIGN: Prospective, randomized trial. SETTING: University-affiliated @entity249 clinic. @entity1 (S): A total of 64 @entity249 @entity1 with @entity1375 , defined as an elevated serum TSH level associated with a normal free T4 level and without frank symptoms of @entity1375 . INTERVENTION(S): @entity1 were randomized into an @entity2016 treatment group or control group. For the @entity2016 treatment group, 50  g @entity2016 was administered from the first day of controlled ovarian stimulation for IVF/ICSI. MAIN OUTCOME MEASURE(S): Results of IVF and pregnancy outcome. RESULT(S): There were no differences in @entity1 characteristics between the two groups. Total dose and days of recombinant @entity1 FSH used for controlled ovarian stimulation were also similar. The number of grade I or II embryos was significantly higher in the @entity2016 treatment group than in the control group. There was no significant difference in the clinical pregnancy rate per cycle between the two groups. However, the miscarriage rate was significantly lower in the @entity2016 treatment group than in the control group. Embryo implantation rate and live birth rate were significantly higher in the @entity2016 treatment group. In the control group, both thyroid peroxidase antibody and thyroglobulin antibody levels were significantly higher in the miscarried subgroup than in the delivered subgroup. CONCLUSION(S): @entity2016 treatment can improve embryo quality and pregnancy outcome in @entity1375 @entity1 undergoing IVF/ICSI.
